Get the full picture
Sign in to uncover key details.
Pheon Therapeutics
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Rothamsted Research, West Common, Harpen...Website
www.pheontx.comRevenue
<$5 MillionIndustry
About Pheon Therapeutics
Pheon Therapeutics is a leading specialist in developing next-generation Antibody-Drug Conjugates (ADCs) aimed at treating a variety of hard-to-treat cancers. With over two decades of experience, the company employs a methodical approach to ADC development, utilizing monoclonal antibodies and proprietary payload platforms to enhance safety and efficacy. Their mission focuses on advancing their lead asset into clinical development while building a proprietary pipeline of follow-on ADCs targeting unmet medical needs in solid tumors. Backed by expert healthcare investors, Pheon boasts a world-class leadership team with expertise in ADC engineering and clinical strategy.Explore more
Pheon Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Pheon Therapeutics
Compare insights from companies similar to Pheon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Pheon Therapeutics Tech Stack
A closer look at the technologies used by Pheon Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pheon Therapeutics
Sign Up For FreeTo access detailed company insights
Pheon Therapeutics is a leading specialist in developing next-generation Antibody-Drug Conjugates (ADCs) aimed at treating a variety of hard-to-treat cancers. With over two decades of experience, the company employs a methodical approach to ADC development, utilizing monoclonal antibodies and proprietary payload platforms to enhance safety and effi... Read More
